Sorafenib Gastric Cancer Asian Phase I Study

• Status: Completed
• Trial end date: 2010-04-01

Summary

This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.

• Phase: Phase 1

Details

• Lead Sponsor: Bayer
• Treatments: Niacinamide; Sorafenib